Skip to main content
Hunan Jiudian Pharmaceutical Co.,Ltd logo

Hunan Jiudian Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 300705 ISIN · CNE1000034Z6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,238 across all filing types
Latest filing 2026-05-29 M&A Activity
Country CN China
Listing Shenzhen Stock Exchange 300705

About Hunan Jiudian Pharmaceutical Co.,Ltd

https://www.hnjiudian.com

Hunan Jiudian Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company maintains a significant focus on transdermal drug delivery systems, particularly medicated patches such as Loxoprofen Sodium Cataplasm. Its therapeutic portfolio encompasses treatments for digestive disorders, respiratory conditions, cardiovascular diseases, and infections. By leveraging an integrated supply chain that spans from chemical synthesis to final product manufacturing, the company produces a variety of formulations including tablets, capsules, and topical preparations. The organization prioritizes advanced formulation technologies to enhance drug bioavailability and patient adherence across its clinical applications.

Recent filings

Filing Released Lang Actions
关于吸收合并全资子公司的进展公告
M&A Activity Classification · 85% confidence The document is a formal corporate announcement by the board of Hunan Jiudian Pharmaceutical Co., Ltd. regarding the progress and completion of absorbing and merging its wholly-owned subsidiary. This constitutes a merger/internal reorganization announcement, fitting the definition of M&A Activity (Code: TAR), which covers announcements related to merger proposals and corporate combination steps. It is not a request for votes, not a financial report, nor a simple regulatory publication notice.
2026-05-29 Chinese
关于九典转02预计触发转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 82% confidence The document is a public disclosure by a Chinese listed company regarding its outstanding convertible bond (“九典转02”) and the expected triggering of conditions for downward adjustment of the conversion price under the bond’s offering terms. There is no financial statement data or meeting minutes; rather it is an update on a financing instrument and potential adjustment to capital structure. This fits the "Capital/Financing Update (CAP)" category.
2026-05-27 Chinese
关于九典转02恢复转股的公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by Hunan Jiudian Pharma regarding the resumption of conversion rights for its convertible bonds (“九典转02”). This is not a full financial report, board change, or earnings release, but an update on the company’s financing instrument and capital structure (convertible bond conversion period). It falls under “Capital/Financing Update (CAP).”
2026-05-25 Chinese
2025年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is a corporate announcement setting out the record date, ex‐dividend date, cash dividend per share, total dividend amount, and implementation details for the 2025 equity distribution. It does not include full financial statements or broader operational commentary—it solely relates to dividend distribution. This matches the “Notice of Dividend Amount” category.
2026-05-21 Chinese
关于九典转02转股价格调整的公告
Capital/Financing Update Classification · 92% confidence The document is an official corporate announcement by Hunan Jiudian Pharmaceutical Co., Ltd. About the adjustment of the conversion price for its outstanding convertible bonds (九典转02). It details the regulatory approvals, formulas for price adjustment in response to dividends and capital changes, and announces the new conversion price effective date. This is not a financial report (10-K/IR) or AGM materials, nor a voting result or proxy statement. It is a financing/capital structure update regarding convertible bonds, fitting the Capital/Financing Update category (CAP).
2026-05-21 Chinese
关于实施权益分派期间九典转02暂停转股的公告
Capital/Financing Update Classification · 75% confidence The document is a corporate announcement regarding the suspension and resumption of conversion rights for a company’s existing convertible bonds during an equity distribution period. This constitutes a financing-related update concerning the company’s capital structure (convertible debt instrument), rather than an actual financial report or dividend amount notice. It fits best under Capital/Financing Update (CAP).
2026-05-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.